Review anchor
Alpha-1A adrenergic receptor
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
Alpha-1A adrenergic receptor
CHEMBL319
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1A adrenergic receptor as ChEMBL target CHEMBL319, mapped to UniProt P43140. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL319
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43140
Alpha-1A adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Alpha-1A adrenergic receptor matters
Alpha-1A adrenergic receptor is reviewed as Alpha-1A adrenergic receptor (UniProt P43140); the current evidence base includes 146 approved drugs, 1868 compounds, and 201 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Alpha-1A adrenergic receptor
Alpha-1A adrenergic receptor Sequence length is 466 aa.
Review this target as Alpha-1A adrenergic receptor, mapped to UniProt P43140. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P43140
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 146 approved drugs, 1868 compounds, and 201 assays for this target. The dominant activity type is KI. CHEMBL1628227 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL1628227 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
146 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Alpha-1A adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43140, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1868
Total Compounds
201
Total Assays
146
Approved Drugs
IC50: 974.0, KI: 1309.0, EC50: 119.0, KD: 191.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1628227
|
11.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL629
|
10.7 | IC50 | Approved |
|
|
No preferred name
CHEMBL836
|
10.5 | Ki | Approved |
|
|
No preferred name
CHEMBL62028
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL293695
|
10.4 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DESVENLAFAXINE
CHEMBL1118
|
2008 |
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
ZIPRASIDONE
CHEMBL708
|
2001 |
|
|
NAFTOPIDIL
CHEMBL142635
|
1999 |
|
|
CITALOPRAM
CHEMBL549
|
1998 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
AZELASTINE
CHEMBL639
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
VENLAFAXINE
CHEMBL637
|
1993 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
DAPIPRAZOLE
CHEMBL1201216
|
1990 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
ASTEMIZOLE
CHEMBL296419
|
1988 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
GUANFACINE
CHEMBL862
|
1986 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
LABETALOL
CHEMBL429
|
1984 |
|
|
PENTAMIDINE
CHEMBL55
|
1984 |
|
|
GUANABENZ
CHEMBL420
|
1982 |
|
|
TRAZODONE
CHEMBL621
|
1981 |
|
|
VERAPAMIL
CHEMBL6966
|
1981 |
|
|
MAPROTILINE
CHEMBL21731
|
1980 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
DOBUTAMINE
CHEMBL926
|
1978 |
|
|
CLEMASTINE
CHEMBL1626
|
1977 |
|
|
PRAZOSIN HYDROCHLORIDE
CHEMBL1558
|
1976 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
CLONIDINE
CHEMBL134
|
1974 |
|
|
DROPERIDOL
CHEMBL1108
|
1970 |
|
|
DOXEPIN
CHEMBL1628227
|
1969 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
EPINEPHRINE
CHEMBL679
|
1965 |
|
|
DESIPRAMINE
CHEMBL72
|
1964 |
|
|
NORTRIPTYLINE
CHEMBL445
|
1964 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
|
|
CYPROHEPTADINE
CHEMBL516
|
1961 |
|
|
FLUPHENAZINE
CHEMBL726
|
1959 |
|
|
IMIPRAMINE
CHEMBL11
|
1959 |
|
|
CHLORPROMAZINE
CHEMBL71
|
1957 |
Source Header